Aim: We studied the possible clinical significance of loss of heterozygosity (LOH) at key tumor suppressor genes loci in advanced renal cancer patients treated with nivolumab. Methods: LOH study was performed on 3p14.2 (FHIT gene); 3p21.3-21.2; 9p21 (BDMF gene); 9p22 (SH3GL2 gene). Results: Of 12 patients, 8 (67%) had LOH. The most affected gene was FHIT. All five patients with LOH at FHIT locus had good outcome, mean progression free survival of 6.8 months. The patients LOH negative at FHIT locus had mean progression free survival of 4 months, 67% were treatment refractory. Overall, 75% of patients with LOH of at least one gene had benefit; 75% of LOH negative cases were refractory. Conclusion: LOH at key tumor suppressor genes should be further investigated as predictive for immunotherapy.

Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab / Silini, Enrico Maria. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 10:9(2018), pp. 743-752. [10.2217/imt-2017-0160]

Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab

Silini
2018

Abstract

Aim: We studied the possible clinical significance of loss of heterozygosity (LOH) at key tumor suppressor genes loci in advanced renal cancer patients treated with nivolumab. Methods: LOH study was performed on 3p14.2 (FHIT gene); 3p21.3-21.2; 9p21 (BDMF gene); 9p22 (SH3GL2 gene). Results: Of 12 patients, 8 (67%) had LOH. The most affected gene was FHIT. All five patients with LOH at FHIT locus had good outcome, mean progression free survival of 6.8 months. The patients LOH negative at FHIT locus had mean progression free survival of 4 months, 67% were treatment refractory. Overall, 75% of patients with LOH of at least one gene had benefit; 75% of LOH negative cases were refractory. Conclusion: LOH at key tumor suppressor genes should be further investigated as predictive for immunotherapy.
Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab / Silini, Enrico Maria. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 10:9(2018), pp. 743-752. [10.2217/imt-2017-0160]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11381/2850981
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 3
social impact